European Medicines Agency recommends to refuse a change to the marketing authorisation for bevacizumab

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion, recommending the refusal of a change to the marketing authorisation for the medicinal product bevacizumab (Avastin). The change concerned an extension of indication to add treatment of glioblastoma. Read more here.